← All trials
NCT01764737
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2012
- Primary completion
- Nov 1, 2014
- Completion date
- Nov 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Vaccinex Inc.Lead sponsor
- University of RochesterOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- North Central Neurology Associates, PCOverall official - principal investigator
- The Neurological Institute, PAOverall official - principal investigator
- MS Center of Northeastern New YorkOverall official - principal investigator
- University of ColoradoOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- Wayne State UniversityOverall official - principal investigator
- Vaccinex Inc.Study director
- University of KansasOverall official - principal investigator
- Pharmaceutical Research Associates, Inc. (PRA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.